ESR1 mutations: moving towards guiding treatment decision-making in metastatic breast cancer patients

Highlights • Mutations in the ligand binding domain of ESR1 lead to ER constitutive activity. • ESR1 mutations are associated with acquired endocrine resistance. • Cell-free DNA is a good substrate for ESR1 mutation detection. • ESR1 mutation analyses have great potential for clinical decision-makin...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 52; pp. 33 - 40
Main Authors Angus, Lindsay, Beije, Nick, Jager, Agnes, W. M. Martens, John, Sleijfer, Stefan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.01.2017
Subjects
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cell-free DNA
DNA Mutational Analysis - methods
Endocrine resistance
ESR1 mutations
Estrogen Receptor alpha - genetics
Female
Hematology, Oncology and Palliative Medicine
Humans
Metastatic breast cancer
Mutation
Neoplasm Metastasis
ESR1 mutations
Cell-free DNA
Metastatic breast cancer
Endocrine resistance
Online AccessGet full text

Cover

More Information
Summary:Highlights • Mutations in the ligand binding domain of ESR1 lead to ER constitutive activity. • ESR1 mutations are associated with acquired endocrine resistance. • Cell-free DNA is a good substrate for ESR1 mutation detection. • ESR1 mutation analyses have great potential for clinical decision-making.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2016.11.001